Jun 19, 2018
AHA Statement before the Senate Committee on Health, Education, Labor and Pensions regarding “Effective Administration of the 340B Drug Pricing Program.”
Jun 6, 2018
AHA Statement to the Committee on Ways and Means for “Hearing on Lowering Costs and Expanding Access to Health Care through Consumer-Directed Health Plans.”
May 24, 2018
AHA provides input regarding action Congress can take to maintain access to health care in rural communities.
May 15, 2018
AHA Statement before the Senate Committee on Health, Education, Labor and Pensions: Examining Oversight Reports on the 340B Drug Pricing Program
May 8, 2018
AHA Statement Before the Committee on Commerce: Improving the Coordination and Quality of Substance Use Disorder Treatment
AHA expresses strong support for legislation that would allow responsible sharing of patient substance use disorder (SUD) treatment information and prevent inappropriate and dangerous prescribing of opioids by amending 42 CFR Part 2 to align with the Health Insurance Portability and Accountability…
Apr 26, 2018
AHA's statement before the House Ways and Means Subcommittee on Health.regarding innovative practices and technology in health care.
Apr 9, 2018
AHA statement before the House Homeland Security Committee on emergency preparedness and lessons learned from Hurricane Harvey.
Mar 21, 2018
Statement of the American Hospital Association before the Subcommittee on Health of the Committee on Ways and Means of the U.S. House of Representatives on Alternative Payment Models (APMs) in the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) on March 21, 2018
The American Hospital Association (AHA) appreciates the opportunity to submit comments on the implementation of alternative payment models (APMs) in the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Now entering its second year, the MACRA’s Quality Payment Program (QPP) continues…
Mar 15, 2018
AHA Statement before the Senate Committee on Health, Education, Labor and Pensions Re: Perspectives on the 340B Drug Pricing Program